Clinical Study
Emergence of Mycoplasma genitalium strains showing mutations associated with macrolide and fluoroquinolone resistance in the region Dresden, Germany

https://doi.org/10.1016/j.diagmicrobio.2016.07.005Get rights and content

Highlights

  • Mycoplasma genitalium was detected in 19 of 323 swabs of male urethritis patients by real-time PCR.

  • In 10 and 2 strains, macrolide or quinolone resistance was confirmed.

  • Analysis of MG309 and MG191 genes shows variability of strains circulated.

Abstract

Among 323 specimens from male patients with symptoms of non-gonococcal urethritis, Mycoplasma genitalium was detected in 19 samples by real-time PCR. Mutations of 23S rRNA gene associated with macrolide resistance were confirmed in 10 strains. Amino acid changes at positions 81 and 83 of ParC protein were demonstrated indicating quinolone resistance of two strains.

Section snippets

Acknowledgement

The authors thank S. Müksch, C. Seiler and C. Thomas for technical assistance.

References (27)

  • T Deguchi et al.

    Drug resistance-associated mutations in Mycoplasma genitalium in female sex workers, Japan

    Emerg Infect Dis

    (2015)
  • PM Dehon et al.

    Mycoplasma genitalium infection is associated with microscopic signs of cervical inflammation in liquid cytology specimens

    J Clin Microbiol

    (2014)
  • DC Gesink et al.

    Mycoplasma genitalium presence, resistance and epidemiology in Greenland

    Int J Circumpolar Health

    (2012)
  • Cited by (41)

    • Molecular basis of antimicrobial resistance in Mycoplasma genitalium

      2020, International Journal of Antimicrobial Agents
    • Mycoplasma genitalium macrolide resistance update: Rate among a 2016–2017 cohort of patients in Barcelona, Spain

      2020, Enfermedades Infecciosas y Microbiologia Clinica
      Citation Excerpt :

      Moxifloxacin (MXF) is currently recommended as second-line antibiotic.5 Nevertheless, MXF resistance is appearing in many countries,19–22 including Spain (<10%),8,23 associated with point mutations in the quinolone resistance determining region (QRDR) of the parC and gyrA genes. In 2016, as a response to the increasing macrolide resistance in M. genitalium and the lack of therapeutic alternatives, international treatment guidelines have recommended AZM to be replaced as the initial treatment for NGU with doxycycline (DOX) 100 mg twice daily for one week.24

    • Mycoplasma genitalium prevalence in Welsh sexual health patients: Low antimicrobial resistance markers and no association of symptoms to bacterial load

      2020, Microbial Pathogenesis
      Citation Excerpt :

      Similar to recent reports from Australia and Canada [7,21], we found MG-MRM rates higher in males (30.8%) compared to females (11.8%). However, our overall MRM rate (20%) was much lower than the 82.4% MRM recently reported for England [22], as well as those reported recently for China (88.9% [15]), Queensland Australia (75.9% [17]), New Zealand (77.4% [23]), Alberta Canada (66.2% [7]), and Germany (52.6% [24]). Our 3.3% overall fluoroquinolone resistance mutation (FRM) rate was similar 4.9% to England (4.9% [22]).

    • Prevalence of macrolide- and fluoroquinolone-resistant Mycoplasma genitalium strains in clinical specimens from men who have sex with men of two sexually transmitted infection practices in Berlin, Germany

      2019, Journal of Global Antimicrobial Resistance
      Citation Excerpt :

      Descriptions of multidrug-resistant strains (combined macrolide and quinolone resistance) and the limited repertoire of well-tested, effective and approved therapy alternatives increase concern regarding untreatable M. genitalium infections [1]. Apart from one report that characterised a small number of samples [7], there is no information about the resistance pattern of M. genitalium strains circulating in Germany. This is especially the case for risk populations.

    View all citing articles on Scopus
    View full text